Pfizer joins forces with Sinopharm to infiltrate China county hospital market
This article was originally published in Scrip
Capturing opportunities presented by a new round of China healthcare reforms, Pfizer is revitalizing a nationwide effort, aiming to upgrade cardiovascular disease diagnosis and treatment inside county-level hospitals.
You may also be interested in...
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.